Study identifier:D0817C00098
ClinicalTrials.gov identifier:NCT04421963
EudraCT identifier:2019-003777-26
CTIS identifier:N/A
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study with Olaparib and Are Judged by the Investigator to Clinically Benefit From Continued Treatment
ovarian cancer
Phase 3
No
Olaparib
All
267
Interventional
18 Years - 99 Years
Allocation: N/A
Endpoint Classification: -
Intervention Model: Sequential Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Sept 2024 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Olaparib Treatment | Drug: Olaparib 300 mg olaparib (2×150 mg tablets) twice daily |